Search Result

Results for "

ovarian cancer xenograft models

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Adrenergic Receptor (1) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Antifolate (1) Apelin Receptor (APJ) (1) Apoptosis (13) Autophagy (1) Bcl-2 Family (4) Beta-secretase (1) c-Myc (1) C-type Lectin-like Receptors (CTLRs) (1) Cadherin (1) CD3 (1) CDK (4) CTLA-4 (1) DNA/RNA Synthesis (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (1) EGFR (1) Ephrin Receptor (1) ERK (2) Fc Receptor (FcR) (1) GABA Receptor (1) GnRH Receptor (1) Histone Methyltransferase (1) HSP (1) Lipase (1) MDM-2/p53 (1) Mesothelin (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) MMP (1) Mps1 (1) mTOR (3) NF-κB (1) PARP (1) Phosphatase (1) PI3K (2) Pim (1) PROTACs (1) Ras (1) Reactive Oxygen Species (ROS) (2) Salt-inducible Kinase (SIK) (1) SHMT (1) TGF-beta/Smad (1) TGF-β Receptor (1) Topoisomerase (1) Transmembrane Glycoprotein (1) Wee1 (1)
By Research Areas:	Cancer (37) Endocrinology (1) Inflammation/Immunology (1)

By Targets:

ADC Antibody (1)

Adrenergic Receptor (1)

Akt (1)

Antibody-Drug Conjugates (ADCs) (1)

Antifolate (1)

Apelin Receptor (APJ) (1)

Apoptosis (13)

Autophagy (1)

Bcl-2 Family (4)

Beta-secretase (1)

c-Myc (1)

C-type Lectin-like Receptors (CTLRs) (1)

Cadherin (1)

CD3 (1)

CDK (4)

CTLA-4 (1)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

Drug-Linker Conjugates for ADC (1)

EGFR (1)

Ephrin Receptor (1)

ERK (2)

Fc Receptor (FcR) (1)

GABA Receptor (1)

GnRH Receptor (1)

Histone Methyltransferase (1)

HSP (1)

Lipase (1)

MDM-2/p53 (1)

Mesothelin (1)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (1)

MMP (1)

Mps1 (1)

mTOR (3)

NF-κB (1)

PARP (1)

Phosphatase (1)

PI3K (2)

Pim (1)

PROTACs (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Salt-inducible Kinase (SIK) (1)

SHMT (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Topoisomerase (1)

Transmembrane Glycoprotein (1)

Wee1 (1)

By Research Areas:

Cancer (37)

Endocrinology (1)

Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-164734

Raludotatug Deruxtecan R-DXd; DS-6000	Antibody-Drug Conjugates (ADCs)	Cancer
Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC₅₀ of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-12929

NSC756093 SU093	Pim Apoptosis	Cancer
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a K_d of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .

HY-163743

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

HY-139852

PLAP-IN-1	Phosphatase	Cancer
PLAP-IN-1 is a selective PLAP inhibitor with an IC₅₀ of 0.032 μM. PLAP-IN-1 acts as a tumor-targeting agent; its fluorescein-conjugated derivative specifically binds to PLAP-positive tumor cells in vitro and targets cervical cancer in mouse xenograft models. PLAP-IN-1 can be used in the research of cervical cancer and ovarian cancer .

HY-177542

Emiltatug ledadotin Emi-Le; XMT-1660		Cancer
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-122650

PHY34	Autophagy	Cancer
PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .

HY-179228

AN02	CTLA-4 TGF-beta/Smad	Cancer
AN02 is a derivative of Curcumin (HY-N0005). AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-175257

Theophylline-platinum(IV) prodrug-1	PARP Reactive Oxygen Species (ROS) Apoptosis NF-κB ERK Bcl-2 Family TGF-β Receptor EGFR Cadherin	Cancer
Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer .

HY-178325

Tubulin-IN-57	Microtubule/Tubulin Apoptosis	Cancer
Tubulin-IN-57 is a Tubulin inhibitor. Tubulin-IN-57 is a potent antiproliferative agent that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Tubulin-IN-57 inhibits tubulin polymerization, which in turn induces G2/M arrest and apoptosis in SKOV3 cells. Tubulin-IN-57 demonstrates potent antitumor activity without observable toxicity in an SKOV3 xenograft model. Y60S can be used for the study of ovarian cancer .

HY-177497

SKLB-03220	Histone Methyltransferase Apoptosis	Cancer
SKLB-03220 is a selective and orally active EZH2 covalent inhibitor with an IC₅₀ of 1.72 nM for EZH2 ^MUT. SKLB-03220 exhibits weak activities against other tested histone methyltransferases (HMTs) and kinases. SKLB-03220 displays noteworthy potency against ovarian cancer cell lines and induces cell apoptosis. SKLB-03220 significantly inhibits tumor growth in PA-1 xenograft model. SKLB-03220 can be used for the study of ovarian cancer .

HY-179525

DL78	c-Myc Microtubule/Tubulin Apoptosis	Cancer
DL78 is an effective anti-mitotic agent. DL78 induces mitotic arrest, mitotic catastrophe and apoptosis in cancer cells by disrupting the interaction between Myc and α-tubulin. DL78 exhibits broad anti-cancer activity, especially against cancer cells with chromosomal instability and excessive expression of MYC. DL78 significantly reduces tumor burden in the OV81.2 xenograft model. DL78 can be used for the study of ovarian cancer .

HY-186132

PROTAC CDK2-pRb degrader-1	PROTACs CDK	Cancer
PROTAC CDK2-pRb degrader-1 is an orally active PROTAC-class degrader of CDK2. PROTAC CDK2-pRb degrader-1 effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine residues 807/811 by inducing ubiquitination and proteasomal degradation of CDK2. PROTAC CDK2-pRb degrader-1 exhibits significant activity against human cells (with EC₅₀ values of 12 nM and 125 nM, respectively). In xenograft models, PROTAC CDK2-pRb degrader-1 effectively inhibits tumor growth and induces tumor stasis, making it suitable for research related to CCNE1-amplified cancers (such as ovarian cancer, gastric cancer, and breast cancer) .

HY-186151

UCI-LC0019	MDM-2/p53 Apoptosis	Cancer
UCI-LC0019 is a mutant p53 reactivator. UCI-LC0019 binds to mutant p53, induces wild-type-like conformational change, restores sequence-specific DNA binding activity, activates p53-dependent transcription programs, and does not act via thiol reactivity or glutathione depletion. UCI-LC0019 inhibits proliferation and induces apoptosis in cancer cells harboring mutant p53, with no significant effect on p53 ^null or wild-type p53 tumors cells. UCI-LC0019 exhibits anti-tumor activity in xenograft mouse models carrying p53^R175H mutant tumors. UCI-LC0019 can be used for the research of cancer, such as ovarian cancer .

HY-156484

SPR519	PI3K mTOR	Cancer
SPR519 is a selective, orally active dual PI3Kα/mTOR kinase inhibitor, with an IC₅₀ of 0.03 μM against PI3Kα and an IC₅₀ of 0.01 μM against mTOR. SPR519 exhibits anticancer effects in ovarian cancer and colon cancer xenograft models. SPR519 can be used for the research of solid tumors (ovarian cancer, colon cancer) .

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

HY-177092

AGF347	Antifolate SHMT Apoptosis mTOR Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Cancer
AGF347 is a potent and multi-targeted antifolate that targets serine hydroxymethyltransferase (SHMT)2 in the mitochondria and SHMT1 in the cytosol, and inhibits de novo purine biosynthesis. AGF347 induces apoptosis, inhibits mTOR signaling, decreases GSH pools, and increases ROS. AGF347 inhibits proliferation of Cisplatin (HY-17394) sensitive and resistant epithelial ovarian cancer (EOC) cells. AGF347 exhibits antitumor efficacy in SKOV3 EOC xenograft mouse models. AGF347 can be used for ovarian cancer research .

HY-176957

PKMYT1-IN-11	Wee1	Cancer
PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC₅₀ of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer .

HY-P992003

IKS012 Antibody IKS01 Antibody	ADC Antibody	Cancer
IKS012 (IKS01) Antibody is a monoclonal antibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .

HY-183601A

Mcl-1-IN-22 hydrochloride	Bcl-2 Family Apoptosis	Cancer
Mcl-1-IN-22 hydrochloride is a tetrahydro-β-carboline-based Mcl-1 inhibitor with a K_i of 0.015 μM. Mcl-1-IN-22 hydrochloride shows antitumor activity, induces apoptosis and produces synergistic antitumor effects in combination with Cisplatin (HY-17394) and Paclitaxel (HY-B0015). Mcl-1-IN-22 hydrochloride can be used for the research of cancer, such as ovarian cancer .

HY-184010

KRASG12D-IN-8	Ras ERK	Cancer
KRASG12D-IN-8 is an orally active KRAS ^G12D inhibitor, with a K_d value of 0.003 nM for KRAS ^G12D and 0.024 nM for KRAS ^G12V. KRASG12D-IN-8 inhibits the activity of phosphorylated ERK in KRAS-mutated cells. KRASG12D-IN-8 induces tumor regression in ovarian cancer xenograft mouse models. KRASG12D-IN-8 can be used for the research of KRAS-mutated cancers .

HY-183329

Tubulin polymerization-IN-92	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-92, an analog of KX-01 (HY-10340), is a potent orally active tubulin polymerization inhibitor that binds tubulin with a K_a of 1.29 μM. Tubulin polymerization-IN-92 simultaneously occupies the colchicine site in β-tubulin and a cavity in α-tubulin. Tubulin polymerization-IN-92 exerts antiproliferative activity, induces G2/M cell cycle arrest and apoptosis in cancer cells. Tubulin polymerization-IN-92 inhibits tumor growth in mouse xenograft models. Tubulin polymerization-IN-92 can be used for the research of colon cancer, cervical cancer, and Paclitaxel (HY-B0015)-resistant ovarian cancer .

HY-179430

TTK-IN-5	Mps1	Cancer
TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC₅₀ = 8.918 nM). TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC₅₀ values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively). TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer .

HY-183601

Mcl-1-IN-22	Bcl-2 Family Apoptosis	Cancer
Mcl-1-IN-22 is a selective Mcl-1 inhibitor with a K_i of 0.015 μM. Mcl-1-IN-22 binds selectively to Mcl-1, disrupts the Mcl-1/Bak complex to release free Bak, triggering intrinsic apoptosis. Mcl-1-IN-22 can be used for the research of ovarian cancer .

HY-181071

POLRMT-IN-3	DNA/RNA Synthesis Drug Intermediate	Cancer
POLRMT-IN-3 is a photosensitive inhibitor of mitochondrial RNA polymerase (POLRMT). POLRMT-IN-3 is biologically inactive in the dark but rapidly releases the active parent compound LJ03 upon illumination with 405 nm light, enabling spatiotemporally precise inhibition of POLRMT. POLRMT-IN-3 exhibits antitumor activity and can be used in research on tumors such as pancreatic cancer and ovarian cancer .

HY-181687

Hsp90-IN-46	HSP CDK	Cancer
Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer .

HY-N1255A

Scoulerine hydrochloride (-)-Scoulerine hydrochloride; Discretamine hydrochloride	Apoptosis PI3K Akt mTOR Adrenergic Receptor GABA Receptor Beta-secretase Bcl-2 Family	Cancer
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine hydrochloride mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine hydrochloride effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine hydrochloride also exhibits multiple pharmacological activities including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine hydrochloride is applicable to research related to leukemia, ovarian cancer, and colorectal cancer .

HY-181540

YL-GB063	Apelin Receptor (APJ)	Cancer
YL-GB063 is an Apelin receptor (APJ) antagonist. YL-GB063 inhibits Apelin-induced APJ β-arrestin recruitment (IC₅₀ of 3.1 μM in HTLA cells). YL-GB063 has anti-cancer activity against ovarian cancer .

HY-183558

AV-DL055	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
AV-DL055 is a conjugate of the toxin molecule Exatecan (HY-13631) and the linker AV-L03 (HY-183678). AV-DL055 can be used to construct ADCs, such as T-DL055 .

HY-181986

ERX-208	Lipase Apoptosis	Cancer
ERX-208 is an anticancer agent that induces endoplasmic reticulum stress by targeting lysosomal acid lipase A (LIPA), ultimately leading to cancer cell apoptosis. ERX-208 can be used in ovarian cancer research .

HY-P992163

23ME-01473	Fc Receptor (FcR) C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology Cancer
23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a K_d of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer .

HY-182312

CTX-439	CDK Apoptosis	Cancer
CTX-439 is an orally active, ATP-competitive small-molecule inhibitor of CDK12 and CDK13, with an IC₅₀ of 3.1 nM and a K_d of 0.38 nM against CDK12, and an IC₅₀ of 9.2 nM against CDK13. CTX-439 induces DNA damage and apoptosis in tumor cells. CTX-439 is applicable for the research of breast cancer and ovarian cancer .

HY-185561

Misitatug blivedotin RC88	Mesothelin	Cancer
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer .

Art. -Nr.	Produktname	Target	Research Area